By Sam Boughedda
Investing.com -- Lantheus Holdings Inc (NASDAQ:LNTH) reported its fourth-quarter and full-year results for 2021, resulting in its shares rallying 32.54% on Thursday.
The developer and manufacturer of diagnostic imaging products reported revenue of $129.56 million, beating analysts' consensus of $111.78 million.
Earnings per share of 25 cents beat analysts' predictions of 16 cents. Full-year earnings also beat forecasts, displaying an impressive year for the stock after launching PYLARIFY, a PSMA PET imaging agent for prostate cancer.
"Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively," said Mary Anne Heino, President and CEO of Lantheus.
"In 2022, we will continue to advance our purpose to Find, Fight and Follow serious medical conditions to improve patient outcomes, and continue to drive revenue growth and shareholder value," she added.
The company has also had a positive start to 2022, with FDA approval for its on-site manufacturing facility.
Lantheus sees revenue of $160 million to $170 million for the first quarter.